Enliven Therapeutics (NASDAQ:ELVN) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Enliven Therapeutics (NASDAQ:ELVN) released its quarterly earnings data on Thursday. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.09, FiscalAI reports.

Enliven Therapeutics Stock Performance

Shares of ELVN traded down $2.46 during mid-day trading on Thursday, reaching $44.79. The stock had a trading volume of 1,585,854 shares, compared to its average volume of 1,673,929. The business has a fifty day moving average of $47.48 and a 200 day moving average of $42.96. The firm has a market cap of $3.28 billion, a price-to-earnings ratio of -26.82 and a beta of 0.34. Enliven Therapeutics has a 12 month low of $14.78 and a 12 month high of $62.32.

Analyst Upgrades and Downgrades

ELVN has been the subject of a number of research analyst reports. Stifel Nicolaus lifted their target price on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Barclays began coverage on Enliven Therapeutics in a report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 price target on the stock. Wall Street Zen downgraded Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Morgan Stanley assumed coverage on Enliven Therapeutics in a research note on Friday, October 2nd. They issued an “overweight” rating and a $70.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Thursday, October 15th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Enliven Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $75.44.

Insider Buying and Selling at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction on Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the sale, the chief financial officer directly owned 38,000 shares in the company, valued at $1,462,240. This trade represents a 13.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director owned 13,000 shares in the company, valued at approximately $606,710. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 31,054 shares of company stock worth $1,493,823 over the last 90 days. Insiders own 3.00% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.